Abstract
Anti-angiogenesis therapy is one major approach of cancer therapies nowadays. Unfortunately, anti-angiogenesis therapy targeting VEGF-A was recently stumbled by the drugresistance that results from adaptive mechanisms, such as intratumor hypoxia. To obtain a more efficient therapeutic response, we created and identified a novel chimeric fusion of VEGF121 and VEGF165, which was connected by Fc region of human IgG1 to enhance dimerization. We found that the treatment of VEGF121-VEGF165 chimeric protein reduces proliferation, migration, invasion, and tube formation in endothelial and/or cancer cells through competing VEGF165 homodimer in a paracrine and an autocrine manner. Furthermore, the fusion protein attenuated autocrine VEGFR2-HIF-1α-VEGF165/Lon signaling through PI3KAKT- mTOR pathway in cancer cells. In conclusion, our data demonstrated that the chimeric VEGF121-VEGF165 arrests the tube formation of endothelial cells and interferes with tumor cell growth, migration and invasion, suggesting that it could be a potential drug as an angiogenesis antagonist in cancer therapy. The VEGF121-VEGF165 targets not only paracrine angiogenic cascade of endothelial cells but also autocrine PI3K-AKT-mTOR-mediated VEGFR2-HIF-1α- VEGF165/Lon signaling that drives drug resistance in tumor cells. Our study will open up the patient opportunities to combat drug resistance to antiangiogenic therapy.
Keywords: Anti-angiogenesis, drug resistance, hypoxia, lon, the chimeric fusion, VEGF121-VEGF165.
Current Cancer Drug Targets
Title:The Novel VEGF121-VEGF165 Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF165/Lon Signaling Through PI3K-AKT-mTOR Pathway
Volume: 16 Issue: 3
Author(s): Jui-Ling Tsai, Yu-May Lee, Chien-Yuan Pan and Alan Yueh-Luen Lee
Affiliation:
Keywords: Anti-angiogenesis, drug resistance, hypoxia, lon, the chimeric fusion, VEGF121-VEGF165.
Abstract: Anti-angiogenesis therapy is one major approach of cancer therapies nowadays. Unfortunately, anti-angiogenesis therapy targeting VEGF-A was recently stumbled by the drugresistance that results from adaptive mechanisms, such as intratumor hypoxia. To obtain a more efficient therapeutic response, we created and identified a novel chimeric fusion of VEGF121 and VEGF165, which was connected by Fc region of human IgG1 to enhance dimerization. We found that the treatment of VEGF121-VEGF165 chimeric protein reduces proliferation, migration, invasion, and tube formation in endothelial and/or cancer cells through competing VEGF165 homodimer in a paracrine and an autocrine manner. Furthermore, the fusion protein attenuated autocrine VEGFR2-HIF-1α-VEGF165/Lon signaling through PI3KAKT- mTOR pathway in cancer cells. In conclusion, our data demonstrated that the chimeric VEGF121-VEGF165 arrests the tube formation of endothelial cells and interferes with tumor cell growth, migration and invasion, suggesting that it could be a potential drug as an angiogenesis antagonist in cancer therapy. The VEGF121-VEGF165 targets not only paracrine angiogenic cascade of endothelial cells but also autocrine PI3K-AKT-mTOR-mediated VEGFR2-HIF-1α- VEGF165/Lon signaling that drives drug resistance in tumor cells. Our study will open up the patient opportunities to combat drug resistance to antiangiogenic therapy.
Export Options
About this article
Cite this article as:
Tsai Jui-Ling, Lee Yu-May, Pan Chien-Yuan and Lee Yueh-Luen Alan, The Novel VEGF121-VEGF165 Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF165/Lon Signaling Through PI3K-AKT-mTOR Pathway, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/156800961603160206125352
DOI https://dx.doi.org/10.2174/156800961603160206125352 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Apoptosis Induction by Ultrasound and Microbubble Mediated Drug Delivery and Gene Therapy
Current Molecular Medicine Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Chemical Modifications and Biological Activities of Polysaccharides
Current Drug Targets Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy Anticancer Agents: VTA or VDA
Current Bioactive Compounds A Roadmap of Cancer: From the Historical Evidence to Recent Salivary Metabolites-based Nanobiosensor Diagnostic Devices
Current Metabolomics and Systems Biology (Discontinued) Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Complex Airway in Childhood Asthma
Current Pediatric Reviews Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine
Current Drug Targets Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging